Goldline Pharmaceutical shareholders and shareholding pattern
BSE: 544759Pharmaceuticals & BiotechnologySmall Cap
Last close ₹30.10up ₹0.12 (0.40%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹29.98.
Range of traded prices from listing on 19 May 2026 to 23 Oct 2026
₹28.13Low, 21 Oct 2026₹60.00High, 19 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29 Cr3,537th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 9 Jun 2026
- 7.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 9 Jun 2026
- 2.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 9 Jun 2026
- 28.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 9 Jun 2026
- 0.64
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,000
Who owns Goldline Pharmaceutical, filing by filing
Per cent of the company's shares. Every filing on record, from Sep 2026; the latest is the filing of 30 Sep 2026.
30 Sep 2026 filing
- Promoters59.54%
- Foreign institutions0.31%
- Indian institutions0.09%
- Individuals and others40.05%
| Per cent | Sep 202630 SepFiled 12 Oct |
|---|---|
| 59.54% | |
| Indian promoters | 59.54% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 40.46% |
| Shares in issue | 96,00,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 69,00,000 |
| Promoters' shares locked in | 54,99,982 |
A dash is a line the filing did not state.
Goldline Pharmaceutical promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing of 30 Sep 2026; the largest is SWAPAN KUMAR KHANDELWAL, 30.08%.Promoter buying and selling
| Holder | |||
|---|---|---|---|
| SWAPAN KUMAR KHANDELWALIndividuals and Hindu undivided families | 30.08% | 28,87,988 | 95.22% |
| AMOL LAXMIKANT MUJUMDARIndividuals and Hindu undivided families | 29.46% | 28,27,988 | 97.24% |
| AISHWARYA AMOL MUJUMDARIndividuals and Hindu undivided families | 0.00% | 3 | 100.00% |
| ASHA KHANDELWALIndividuals and Hindu undivided families | 0.00% | 3 | 100.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Goldline Pharmaceutical, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 202630 SepFiled 12 Oct |
|---|---|
| SUMIT BILGAIYANResident individuals, over ₹2 lakh at face value | 7.06% |
| PRIYA CHANDRAKANT JALGAONKARResident individuals, over ₹2 lakh at face value | 2.34% |
| SGMP MANAGEMENT CONSULTANCY PRIVATE LIMITEDCompanies | 1.98% |
| MEENA NAYAN PATELResident individuals, over ₹2 lakh at face value | 1.04% |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.